Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
$1.59+0.05 (+3.25%)
Close on Nov 11, 2026Market cap $149.01MP/E –Yield –
Innate Pharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Innate Pharma's enterprise value was $135.25M on Nov 11, 2026, against $95.75M a year earlier. Over the last 5 years it ranged from $50.08M to $242.26M, with a median of $113.24M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $135.25M | +71.6% |
| 2025 | Dec 31, 2025 | $78.81M | +4.3% |
| 2024 | Dec 31, 2024 | $75.59M | -47.5% |
| 2023 | Dec 29, 2023 | $143.99M | -22.8% |
| 2022 | Dec 30, 2022 | $186.56M | -23.0% |
| 2021 | Dec 31, 2021 | $242.26M | +849.1% |
| 2020 | Dec 31, 2020 | $25.52M | -87.7% |
| 2019 | Dec 31, 2019 | $207.52M | – |
See a number that looks wrong?